| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $70,422 | 3 | 100 |
| Mahmood Nadir | President | 0 | $0 | 1 | $11,693 | $-11,693 |
| HASTINGS PAUL J | Chief Executive Officer | 0 | $0 | 2 | $58,728 | $-58,728 |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The …
Over the last 12 months, insiders at Nkarta, Inc. have bought $0 and sold $70,422 worth of Nkarta, Inc. stock.
On average, over the past 5 years, insiders at Nkarta, Inc. have bought $46.5M and sold $345,388 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,000,000 shares for transaction amount of $30M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑27.
| 2026-06-18 | Sale | HASTINGS PAUL J | Chief Executive Officer | 1,776 0.0024% | $2.71 | $4,813 | -9.79% | |
| 2026-01-15 | Sale | HASTINGS PAUL J | Chief Executive Officer | 26,046 0.0387% | $2.07 | $53,915 | +29.59% | |
| 2026-01-15 | Sale | Mahmood Nadir | President | 5,649 0.0084% | $2.07 | $11,693 | +29.59% | |
| 2025-06-18 | Sale | HASTINGS PAUL J | Chief Executive Officer | 1,790 0.0025% | $1.79 | $3,204 | +17.58% | |
| 2025-01-15 | Sale | HASTINGS PAUL J | Chief Executive Officer | 17,378 0.0241% | $2.20 | $38,232 | -12.50% | |
| 2025-01-15 | Sale | Shook David | See Remarks | 8,638 0.012% | $2.20 | $19,004 | -12.50% | |
| 2025-01-15 | Sale | Hager Alicia J. | Chief Legal Officer | 9,584 0.0133% | $2.20 | $21,085 | -12.50% | |
| 2025-01-15 | Sale | Brandenberger Ralph | Chief Technical Officer | 7,447 0.0103% | $2.20 | $16,383 | -12.50% | |
| 2025-01-15 | Sale | Levin Alyssa | See Remarks | 5,838 0.0081% | $2.20 | $12,844 | -12.50% | |
| 2024-07-16 | Sale | Hager Alicia J. | Chief Legal Officer | 3,396 0.0065% | $8.00 | $27,168 | -70.63% | |
| 2024-06-18 | Sale | HASTINGS PAUL J | Chief Executive Officer | 1,770 0.0022% | $5.60 | $9,912 | -52.85% | |
| 2024-06-18 | Sale | Trager James | Chief Scientific Officer | 456 0.0006% | $5.60 | $2,554 | -52.85% | |
| 2024-06-18 | Sale | Shook David | Chief Medical Officer | 456 0.0006% | $5.60 | $2,554 | -52.85% | |
| 2024-06-18 | Sale | Hager Alicia J. | Chief Legal Officer | 727 0.0009% | $5.60 | $4,071 | -52.85% | |
| 2024-06-18 | Sale | Brandenberger Ralph | Chief Technical Officer | 229 0.0003% | $5.60 | $1,282 | -52.85% | |
| 2024-03-27 | RA CAPITAL MANAGEMENT, L.P. | 3M 5.4767% | $10.00 | $30M | -58.16% | |||
| 2024-03-27 | George Simeon | director | 2M 3.6511% | $10.00 | $20M | -58.16% | ||
| 2024-03-01 | Sale | Brandenberger Ralph | Chief Technical Officer | 8,367 0.0167% | $12.51 | $104,671 | -59.03% | |
| 2024-02-12 | Sale | Trager James | Chief Scientific Officer | 4,143 0.0088% | $12.00 | $49,716 | -52.34% | |
| 2024-01-16 | Sale | HASTINGS PAUL J | Chief Executive Officer | 9,697 0.02% | $8.74 | $84,752 | -31.65% |
| RA CAPITAL MANAGEMENT, L.P. | 10050818 14.0326% | $15.38M | 3 | 0 | <0.0001% | |
| GLAXOSMITHKLINE PLC | 3150732 4.3989% | $4.82M | 1 | 0 | <0.0001% | |
| MAKOWER JOSHUA | 10 percent owner | 2902115 4.0518% | $4.44M | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | 10 percent owner | 2902115 4.0518% | $4.44M | 1 | 0 | <0.0001% |
| BASKETT FOREST | 10 percent owner | 2902115 4.0518% | $4.44M | 1 | 0 | <0.0001% |
| Sonsini Peter W. | 10 percent owner | 2902115 4.0518% | $4.44M | 1 | 0 | <0.0001% |
| Florence Anthony A. Jr. | 10 percent owner | 2902115 4.0518% | $4.44M | 1 | 0 | <0.0001% |
| New Enterprise Associates 15, L.P. | 10 percent owner | 2902115 4.0518% | $4.44M | 1 | 0 | <0.0001% |
| Makhzoumi Mohamad | 10 percent owner | 2902115 4.0518% | $4.44M | 1 | 0 | <0.0001% |
| Novo Holdings A/S | 10 percent owner | 2793865 3.9007% | $4.27M | 1 | 0 | <0.0001% |
| George Simeon | director | 1548341 2.1617% | $2.37M | 2 | 0 | <0.0001% |
| Flynn James E | director | 1209936 1.6893% | $1.85M | 1 | 0 | <0.0001% |
$5,552,811 | 165 | 5.84% | $106.2M | |
$16,280,851 | 76 | 1.48% | $118.27M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
$130,095 | 43 | 45.19% | $111.24M | |
$47,438,336 | 33 | -21.38% | $122.37M |
| Increased Positions | 54 | +41.22% | 8M | +13.62% |
| Decreased Positions | 51 | -38.93% | 10M | -16.8% |
| New Positions | 19 | New | 4M | New |
| Sold Out Positions | 12 | Sold Out | 193,317 | Sold Out |
| Total Postitions | 134 | +2.29% | 56M | -3.18% |
| Ra Capital Management, L.P. | $20,206.00 | 15.22% | 10.81M | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $13,194.00 | 9.94% | 7.06M | 0 | 0% | 2025-09-30 |
| Samsara Biocapital, Llc | $7,046.00 | 5.31% | 3.77M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $6,916.00 | 5.21% | 3.7M | -455,308 | -10.96% | 2025-09-30 |
| Nea Management Company, Llc | $6,674.00 | 5.03% | 3.57M | 0 | 0% | 2025-09-30 |
| Sr One Capital Management, Lp | $6,233.00 | 4.7% | 3.33M | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $5,423.00 | 4.08% | 2.9M | -398,066 | -12.07% | 2025-09-30 |
| Vanguard Group Inc | $4,660.00 | 3.51% | 2.49M | -62,565 | -2.45% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $3,898.00 | 2.94% | 2.08M | 0 | 0% | 2025-09-30 |
| Monaco Asset Management Sam | $3,686.00 | 2.78% | 1.97M | +387,538 | +24.48% | 2025-09-30 |